This study demonstrates PEGylation lowers mucin adhesion of β–cyclodextrins, indicating improved drug transport across mucosal barriers.
β–Cyclodextrin (β–CD)-based materials are widely used in drug delivery, yet their interactions with mucosal barriers remain insufficiently understood. Because the mucus layer coating epithelial surfaces can hinder drug transport, elucidating β–CD–mucin interactions is critical for optimizing cyclodextrin-based carriers. In this study, we examined whether PEGylation can attenuate the mucoadhesive behavior of β–CD. Monomethoxy poly(ethylene glycol)-modified β–CDs (MPEG–β–CDs) were evaluated using 19F self-diffusion NMR spectroscopy coupled with a kinetic diffusion model describing reversible binding to stationary substrates. Mucin hydrogels were prepared from bovine submaxillary mucin and served as a model mucus environment. Diffusion coefficients were extracted from the 19F NMR signals of 1-fluoroadamantane (1FA) molecules encapsulated within HP-β–CD or MPEG–β–CD cavities. The results demonstrate that PEGylation substantially reduces β–CD–mucin adhesion, with longer PEG chains (2000 Da) providing more effective steric shielding than shorter chains (500 Da). These findings indicate that PEGylation can protect β–CD-included drugs during transport across mucosal barriers by minimizing unwanted β–CD–mucin interactions.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: